Overview

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Status:
RECRUITING

Trial end date:
2026-10-14

Target enrollment:

Participant gender:

Summary

Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic response in AL patients with favorable safety profile. As an oral agent with encouraging data, it is worth to prospectively evaluate the efficacy and safety of venetoclax combined with daratumumab and dexamethasone in untreated AL amyloidosis patients.

Phase:

PHASE2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

daratumumab
Dexamethasone
Injections, Subcutaneous
venetoclax